insulin glulisine vs Insulin lispro (Lyumjev)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

Insulin lispro (Lyumjev)

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Partial signal

NCT03214380 · Phase 3 · completed

The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)

Result source: NCT03952143

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glulisineInsulin lispro (Lyumjev)
HbA1c, change-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
Body weight, change (kg)0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
—Not reported
HbA1c below 7%22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
—Not reported
Fasting plasma glucose, change—Not posted · NCT00135057—Not reported
3-point MACE (% with event)—Not posted · NCT00135057—Not reported

HbA1c, change

insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
Insulin lispro (Lyumjev)
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143

Body weight, change (kg)

insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
Insulin lispro (Lyumjev)
—Not reported

HbA1c below 7%

insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
Insulin lispro (Lyumjev)
—Not reported

Fasting plasma glucose, change

insulin glulisine
—Not posted · NCT00135057
Insulin lispro (Lyumjev)
—Not reported

3-point MACE (% with event)

insulin glulisine
—Not posted · NCT00135057
Insulin lispro (Lyumjev)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin glulisine: 4 of 4 rows · Insulin lispro (Lyumjev): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glulisineInsulin lispro (Lyumjev)
Dropout rate
23.5%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
2.6%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Serious AEs
11.9%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
7.7%b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.4%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
0%LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
b
nasopharyngitis 14%
upper respiratory tract infection 8%
diarrhoea 3.3%
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
upper respiratory tract infection 5.3%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
injection site reaction 5.6%
NCT03341312 · Phase 1 · registry result, not featured evidence
injection site reaction 2.9%
NCT03341312 · Phase 1 · registry result, not featured evidence
15 U
headache 10%
nausea 5%
injection site reaction 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
30 U
headache 14.6%
injection site reaction 14.6%
nausea 7.3%
NCT03286751 · Phase 1 · registry result, not featured evidence
7 U
headache 15%
injection site reaction 2.5%
nausea 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
15 U
headache 5.3%
vessel puncture site thrombosis 5.3%
NCT03305822 · Phase 1 · registry result, not featured evidence
15 U
infusion site pain 12%
catheter site bruise 8%
vessel puncture site bruise 8%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
injection site pain 11.5%
application site erythema 7.7%
catheter site bruise 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site pain 10.7%
catheter site swelling 7.1%
application site erythema 3.6%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site bruise 7.7%
infusion site erythema 7.7%
infusion site swelling 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
headache 6.7%
back pain 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
back pain 0%
headache 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
thrombophlebitis 6.9%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
thrombophlebitis 10.3%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glulisine

HbA1c Less Than 7% 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7% 51.1% (n=180) vs 39.5% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
22.4% (n=49) vs 8.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
absolute value · percentage points
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk
absolute change · mmol/L
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
Weight 0.46 vs 0.22 Insulin Glargine+Metformin+Glimepiride kg @ 24wk
absolute change · kg
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.5 vs 1.6 Insulin-lispro kg*
NCT01194258 · Phase 2 · registry result, not featured evidence · converted to kg from 3.35 pounds as posted
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

Insulin lispro (Lyumjev)

HbA1c 7.0 or Less 58.2% (n=316) vs 52.5% (n=320) Insulin Lispro (Humalog) @ 26wk
event count · % of participants
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 184 Participants as posted
PPG 1H Excursion mg/dL 86.2 vs 100.8 Insulin Lispro (Humalog) mg @ 26wk
absolute value · mg
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2 h Excursion mg/dL 6.18 vs 7.39 Insulin Lispro (Humalog) mmol/L @ 26wk
absolute value · mmol/L
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 111.4 mg/dL as posted
HbA1c Less Than 7% 46.65% (n=358) vs 44.5% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c < 7%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6 5 or Less 27.93% (n=358) vs 27.23% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c ≤ 6.5%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range Daytime 3.8 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c -0.44% (n=167) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range 24 h 3.3 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Below 54 0 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 180 -3.4 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 2.50 -1.07 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0 1H -2.46 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · Insulin lispro (Lyumjev)'s landscape